Virtual Library

Start Your Search

H. Cheng



Author of

  • +

    OA20 - Immunotherapy and Markers (ID 401)

    • Event: WCLC 2016
    • Type: Oral Session
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      OA20.07 - HHLA2, a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status (ID 5184)

      11:00 - 12:30  |  Author(s): H. Cheng

      • Abstract
      • Presentation
      • Slides

      Background:
      Immunotherapy with antibodies against B7/CD28 family members, including PD-1, PD-L1, and CTLA-4 has shifted the treatment paradigm for non-small-cell lung carcinoma (NSCLC) with improved clinical outcome. HHLA2 is a newly discovered member of the family. By regulating T-cell function, HHLA2 could contribute to tumor immune suppression and thus be a novel target for cancer immunotherapy. There is limited information and critical need to characterize its expression profile and clinical significance in NSCLC.

      Methods:
      We performed immunohistochemistry with an HHLA2-specific antibody (clone 566.1) using tissue microarrays constructed from 679 NSCLC tumor tissues, including 392 cases in the discovery set and 287 cases in the validation cohort. We also studied clinico-pathological characteristics of these patients.

      Results:
      Overall, HHLA2 was not detected in most of normal lung tissue but expressed in 66% of NSCLC across different subtypes. In particular, EGFR–mutated NSCLC was significantly associated with higher tumor HHLA2 expression in both discovery (EGFR vs. WT: 76% vs. 53%, P=0.01) and validation cohorts (89% vs. 69%, P=0.01). In one of the two cohorts, HHLA2 expression was higher in lung adenocarcinoma as compared to squamous and large cell histology, non-Hispanic White vs. Hispanics, and tumors with high tumor infiltrating lymphocyte (TIL) density. In the multivariate analysis, EGFR mutation status and high TIL intensity were independently associated with HHLA2 expression in lung adenocarcinoma.

      Conclusion:
      HHLA2 is widely expressed in NSCLC and is associated with EGFR mutation and high TILs in lung adenocarcinoma. It is potentially a novel target for lung cancer immunotherapy.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Poster Session with Presenters Present (ID 461)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P2.01-056 - Distinct PD-L1 Expression in Different Components of Pulmonary Sarcomatoid Carcinoma and Its Association with MET Mutation (ID 5228)

      14:30 - 15:45  |  Author(s): H. Cheng

      • Abstract
      • Slides

      Background:
      Pulmonary Sarcomatoid Carcinoma (PSC) is a unique and highly aggressive subtype of non-small cell lung cancer (NSCLC), characterized by a component of sarcoma or sarcoma-like differentiation. It is generally resistant to platinum-based chemotherapy. However, frequent KRAS and the MET exon 14 skipping mutations have been reported in this subtype. Recently, immunotherapy with antibodies against PD-1/PD-L1 has led to clinical benefits in managing NSCLC. Immune biomarker expression of PD-L1 in differential components of PSC and its relationship with other molecular markers has not been defined and thus there is critical need to investigate its expression profile in this deadly disease.

      Methods:
      We investigated PD-L1 expression by immunohistochemistry (IHC) using tissue microarrays from a cohort of 41 patients with PSC (antibody: PD-L1/CD274 (SP142)). Positive cases were defined as PD-L1 ≥ 1%. The clinical and molecular characterization of these cases was previously reported (PMID: 26215952). Among the 41 cases, 36 had sufficient tumor tissue for PD-L1 assessment, 8 (20%) were identified with MET exon 14 skipping mutation and 6 (15%) were found to have KRAS mutations.

      Results:
      The PD-L1 expression was positive in 75% (27/36) of cases. Among the positive cases, 78% expressed PD-L1 ≥ 50%, whereas 22% had PD-L1 staining of 1-49%. Interestingly, only 33% (9/27) had PD-L1 expression in both epithelial and sarcomatoid components, whereas the remaining 66% detected PD-L1 in just one component. The PD-L1 expression was statistically different between the two components (P=0.007). Moreover, all 8 patients with MET exon 14 skipping mutation were PD-L1 positive (6 with PD-L1 ≥ 50%), whereas 5 of 6 patients with KRAS mutation expressed PD-L1 (2 with PD-L1 ≥ 50%). The average age at diagnosis was similar between the PD-L1 positive vs. negative groups (71 years). There was a trend of shorter overall survival in patients whose tumors were positive for PD-L1 (671 vs. 985 days).

      Conclusion:
      In our particular cohort of PSC patients, high PD-L1 (≥ 50%) was expressed in the large majority of cases which favors potential application of immunotherapy in this disease. In addition, it appears that the expression of PD-L1 is different in the epithelial and sarcomatoid components which could affect scoring in practice. Furthermore, the overall positivity of PD-L1 expression in the unique molecular subtype of PSC patients with MET exon 14 skipping mutation indicates potential interplay between the two biomarkers and suggests that exploration of combination MET and immunotherapy in this subtype is warranted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.